Using bone marrow concentrate to treat ACL tears
Using Autologous Bone Marrow Aspirate Concentrate to Treat Complete Anterior Cruciate Ligament Tear.
This study is testing whether using a patient's own bone marrow to treat ACL tears can help them heal better and get back to their normal activities.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 20 (estimated) |
| Ages | 20 Years to 55 Years |
| Sex | All |
| Sponsor | Global Stem Cell Center, Baghdad Industry-sponsored |
| Locations | 1 site (Baghdad) |
| Trial ID | NCT06353503 on ClinicalTrials.gov |
What this trial studies
This study investigates the use of autologous bone marrow aspirate concentrate (BMAC) as a treatment for complete and partial anterior cruciate ligament (ACL) tears. It involves a single-arm multicenter approach enrolling 20 patients, where BMAC is extracted from the patient's own bone marrow and injected into the knee joint under ultrasonic guidance. The goal is to leverage the regenerative properties of BMAC, which contains stem cells and growth factors, to promote healing and restore knee functionality. The study specifically targets individuals aged 20 to 55 who have sustained sports-related ACL injuries.
Who should consider this trial
Good fit: Ideal candidates are individuals aged 20 to 55 with confirmed complete or partial ACL tears.
Not a fit: Patients with bleeding disorders, a history of malignancy, or significant comorbidities may not benefit from this study.
Why it matters
Potential benefit: If successful, this treatment could provide a less invasive alternative to surgical reconstruction for ACL tears, potentially improving recovery times and outcomes.
How similar studies have performed: While the use of BMAC in orthopedic applications is gaining interest, this specific approach for ACL tears is relatively novel and has not been extensively tested in prior studies.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1- Confirmed diagnosis of complete or partial ACL tear via clinical examination and imaging studies. 2\. Aged between 20 and 55 years, to encompass the typical age range of patients with sports-related ACL injuries. Exclusion Criteria: 1- Patients with a history of bleeding disorders, as this could complicate the aspiration and injection procedures. 2\. Individuals with a history of malignancy, due to the potential risks associated with growth factors present in BMAC. 3\. Critically ill patients or those with comorbidities
Where this trial is running
Baghdad
- Ministry of Health — Baghdad, Iraq (Recruiting)
Study contacts
- Study coordinator: abdulmajeed A hammadi, MD
- Email: majeed51578@yahoo.co.uk
- Phone: +9647902268105
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.